An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

Table 2 Primary endpoints

	n	0 M	6 M	Change	Mean value difference
	n	0 M	6 M	Change	p value
GA (%)	12	22.9 (20.8, 26.1)	21.2 (19.4, 22.5)	− 1.8 (− 6.6, − 0.3)	0.026
HbA1c (%)	9	6.8 (6.2, 7.1)	6.3 (5.4, 6.7)	− 0.4 (− 1.2, 0.2)	0.172
Pre-dialysis BG (mg/dl)	12	134.5 (117.3, 196.5)	149.5 (121.8, 215.3)	25.0 (− 23.3, 68.0)	0.239
Mean BG in CGM (mg/dl)	12	171.4 (160.4, 202.7)	156.1 (147.0, 166.1)	− 18.8 (− 42.0, 17.2)	0.158
SD of BG in CGM (mg/dl)	12	47.2 (35.9, 58.4)	38.1 (32.5, 47.9)	− 10.6 (− 20.2, 5.9)	0.099
MAGE (mg/dl)	12	114.4 (83.4, 134.7)	91.0 (79.2, 128.5)	− 21.7 (− 47.7, 14.1)	0.209
AUC > 180 in CGM (mg·24 h/dl)	12	93.1 (52.8, 239.3)	46.8 (20.9, 75.4)	− 58.6 (− 141.0, 26.8)	0.117
AOC > 70 in CGM (mg·24 h/dl)	12	0.0 (0.0, 0.2)	0.0 (0.0, 0.1)	0.0 (− 0.2, 0.0)	0.917
Insulin dose (U/day)	12	24.5 (15.0, 45.5)	6.0 (0.0, 18.0)	− 15.0 (− 24.5, − 9.4)	0.002

Data are expressed as median (interquartile range). The change indicates changes from baseline to 24 weeks
GA, glycated albumin; HbA1c, glycated hemoglobin; BG, blood glucose; CGM, continuous glucose monitoring; SD, standard deviation; MAGE, mean amplitude of glycemic excursions; AUC, area under the curve; and AOC, area over the curve

ISSN: 2059-1381